Pathios Therapeutics Limited Revenue and Competitors

Oxford, UK

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Pathios Therapeutics Limited's estimated annual revenue is currently $3.4M per year.(i)
  • Pathios Therapeutics Limited's estimated revenue per employee is $155,000

Employee Data

  • Pathios Therapeutics Limited has 22 Employees.(i)
  • Pathios Therapeutics Limited grew their employee count by 10% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3.4M2210%N/AN/A
#2
$3.1M20-9%N/AN/A
#3
$9.1M5937%N/AN/A
#4
$10.9M7013%N/AN/A
#5
$20.6M1336%N/AN/A
#6
$3.4M2210%N/AN/A
Add Company

Pathios Therapeutics is an early-stage drug discovery company that was established in 2017 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs. Based in Oxford, UK, the company is founded upon a deep understanding of the biology of tumour-associated macrophages (TAMs). We are currently engaged in a fully-enabled drug discovery program to identify novel small-molecule modulators of GPR65 with expected utility across a broad spectrum of cancers. We are also more broadly interested in the potential to target GPR65 for benefit in a range of other serious diseases. Pathios employs a cutting-edge scientific approach to mapping the signalling of key GPCRs on immune cells based on human genetic insights, transcriptomics and state-of-the-art cellular immunology. By leveraging a range of proprietary insights emerging from this approach Pathios has identfied GPR65 as a key innate immune checkpoint on TAMs and now aims to rapidly deliver on the promise of novel therapeutic agents targeting this receptor. We combine a team of experienced scientific leaders with a number of strategic external partnerships to efficiently carry out a range of drug discovery and scientific activities, capitalising on the very latest advances in GPCR drug discovery.

keywords:N/A

N/A

Total Funding

22

Number of Employees

$3.4M

Revenue (est)

10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Pathios Therapeutics Limited News

2022-04-06 - Pathios Therapeutics Highlights Role of GPR65 as Critical ...

OXFORD, United Kingdom, April 12, 2022 /PRNewswire/ -- Pathios Therapeutics Limited ("Pathios"), a biotech company focused on the...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.5M22-19%N/A
#2
$3.2M22-4%N/A
#3
N/A22-21%N/A
#4
$3.9M220%N/A
#5
$3.4M2210%N/A